wp5 - protectprotect-h2020.eu/wp-content/uploads/2017/05/ko_wp5...gantt wp5 wp/t no. wps/tasks name...

Brussels, Belgium Kick Off Meeting , January , 201723-24

WP5

End products manufacturing in relevant industrial environment

and their characterization

Leader AITEX

Partners: UPC, BIU, CNR, CENTI, CSIC, KLO, PER, MAR, DGA, CDB, CTEC, FN,

INDA, ICONE, SYN, PRJ, NSC

https://www.google.co.il/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwidjvmMvLDQAhXC6xoKHbeDAj0QjRwIBw&url=https://spie.org/membership/spie-professional-magazine/spie-professional-archives-and-special-content/2014_jan_archive_spie_pro/horizon2020&psig=AFQjCNH1Fb3xxKgUSP6XWJQwCzyMtBzF8w&ust=1479495426330485


Objectives/Tasks

1. Production of antimicrobial textiles, anti-biofilm membranes and anti-biofilm biocompatible medical devices (Task 5.1)

2. Characterisation of the end products by common tests (Task 5.2)

3. Antimicrobial/anti-biofilm efficiency and biocompatibility of the end products (Task 5.3)

4. Anti-biofilm performance of water filtration membranes in water scarce area (Sicily) (Task 5.4)



Gantt WP5

WP/T

No. WPs/Tasks Name

Year 2 Year 3 Year 4

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

WP5 End products manufacturing in relevant industrial

environment and their characterization

T5.1 Production of the end products

T5.2 Characterisation of the end products by common tests D5.

1

T5.3 Antimicrobial/anti-biofilm efficiency and biocompatibility

of the end products

D5.

2

T5.4 Anti-biofilm performance of water filtration membranes

in water scarce area (Sicily)

D5.

3

T5.5 Conclusion regarding the technology and most efficient

NPs for each of the end products

D5.

4

Starting date: M13 (Jan’18) - End date: M48 (Dec’20)



Work Plan WP5 - General overview

Task 5.1. Production of antimicrobial textiles, anti-biofilm membranes

and anti-biofilm biocompatible medical devices (Leader: KLO)

• Partners KLO and MAR, hosting the two R2R pilots, will produce

upholstery and medical textiles.

• They will also coat the water treatment membranes supplied by partner

CDB. The coated membranes will be sent to partner CDB for filters

production (specifications of the filtering element from partner FN).

• Partner PER will receive the antibacterial textiles from partner KLO and

will further design and produce the pyjamas/bedding for hospitals.

products.

• Partner DGA, hosting the batch pilot, will produce anti-biofilm medical

devices (coating the catheters).

• Other involved partners: ICONE, INDA, CTEC and NSC.



Technology Products Quantity Partner

hosting the pilot

Partner

producing the end product

R2R Spray coating

2D

one side coating

Upholstery fabrics

for public areas 1000 m2

MAR MAR Water treatment

membranes 400m2

Reverse Osmosis (RO)

filters for drinking water

using the anti-biofilm

membranes coated at MAR

100 units CDB

R2R US coating

2D

both sides coating

Hospital textiles 2000 m2

KLO KLO Water treatment

membranes 400 m2

Hospital pyjamas and

beddings using the

antimicrobial fabrics coated

at KLO

200 pyjamas

200 beddings PER

Reverse Osmosis (RO)

filters for drinking water

using the anti-biofilm

membranes coated at KLO

100 units CDB

Batch US

coating

3D entire surface

Urinary catheters 1000 units DGA DGA

Products to be developed in Task T5.1. - Summary




Task 5.2. Characterisation of the end products by common tests

(Leader: AITEX)

Upholstery and medical fabrics:

• Tensile strength and elongation (ISO 13934-1), sample size: 30x5cm

• Weight measurement (EN 12127), sample size: 20x20cm

• Pilling + abrasion resistance (ISO 12945-2 and ISO 12947-3). Size: 20x20cm

• Simulated outdoor ageing (only for upholstery fabrics).

Water treatment membranes:

• Pressure drop measurement (EN 13443-1) initial filtration efficiency (ASTM D

4751).

Other tests and characterizations on all functional end-products:

• SEM, AFM, DSC, ICP-MS and cytotoxicity (ISO 10993-5; size: 15x15cm).

Involved partners: AITEX, UPC, BIU and CENTI.




Task 5.3. Antimicrobial/anti-biofilm efficiency and biocompatibility of

the end products (Leader: AITEX)

5.3.1. Antimicrobial efficiency of the functional textiles

• Testing will cover the most widely spread hospital pathogens, e.g. P. aeruginosa,

A. baumannii, Enterobacteriaceae, Methicillin-resistant Staphylococcus aureus

(MRSA) and multi drug resistant E. coli. (a,b).

• AATCC and ISO tests: AATCC 100 and ISO 20743 (bacteria) and AATCC 30

(fungi). Sample size for each test: 15x15cm.

• Bedding and pyjamas will also be tested as a function of the number of washing

cycles: 15, 25, and 60 washing cycles at 60ºC (ISO 105-C06).

Involved partners: AITEX, BIU, UPC






5.3.2. Antimicrobial/anti-biofilm efficiency and biocompatibility for medical

devices (catheters). Involved partner: UPC.

• Measurement of antibacterial activity (ISO 22196:2011) against most relevant

bacteria: P. aeruginosa, A. baumannii, and the Enterobacteriaceae.

• Total bioburden of the medical devices (ISO 11737-1).

• Cytotoxicity (ISO 10993-5; size: 15x15cm).

• In-vitro models and tests for anti-biofilm activity of indwelling devices will be

routinely carried out. Additionally, fluorescence microscopy will be used.

• The viable cells in the biofilm per gram catheters will be also assessed after

counting the number of colony forming units after plating the cultures on specific

agar.

• The efficiency of the antimicrobial/anti-biofilm coatings on urinary catheters will

be further evaluated under dynamic conditions using an in vitro model of

catheterised human bladder.






5.3.3. Antimicrobial/anti-biofilm efficiency of water treatment membranes

• The antibacterial functionality of the filter media will be evaluated (ISO 22196).

• Tests for S. aureus, Microcystis aeruginosa and M. panniformis.

• For the anti-biofilm activity of the membranes two types of tests will be

performed: inhibition test (monitoring the capacity of the bioactive membrane in

inhibiting biofilm formation) and detachment test (evaluating the potential of the

membrane in degrading and dissolving a fully formed bacterial biofilm) tests.

Involved partners: AITEX and BIU.


Brussels, Belgium Kick Off Meeting 23-24 January, 2017

Antibiofilm assays

Static biofilm model

Flow biofilm model

Total biomass

% live bacteria

Microscopy

SEM Florescence

Task 5.3 Antibiofilm characterization of the end products (BIU)



Total biofilm biomass quantification assay

Washing

the

unattached

cells

Crystal

Violet

staining

Ethanol

extraction Spectrophotometer

measurement Biofilm

quantifica

tion




Transforming bacteria l strain into a GFP-

expressing one

Biofilm is developed on

coatings

Cell scraping

Fluorescence measurement

Cell plaiting

Viable counts




Treatm

ent

Control Gm

Confo

cal

SEM

Task 5.3 Antibiofilm characterization

of the end products (BIU)



Range of bacterial strains: Escherichia coli Staphylococcus aureus Pseudomonas aeruginosa MDR strains like MRSA Natural Strains Evaluate biofouling in natural settings (e.g membrane systems)





Task 5.4. Anti-biofilm performance of water filtration membranes in

water scarce area (Sicily) (Leader: CDB)

FN will test the efficiency of the anti-biofilm membranes in the municipal

water filtration systems of Catania and Gela.

• Life time of the filter – its anti-biofilm efficiency during 2, 5 and 10 days.

• The quality of the drinking water by the usual procedure used by FN.

Other involved partners: CDB, DGA, MAR, KLO, BIU, CENTI, ICONE, INDA

and CTEC (discussion and analysis of results, in order to conclude optimal

ways for improvements).

Task 5.5. Conclusion regarding the technology and most efficient NPs

for each of the end products (Leader: UPC)

The results of the different tests will be analysed and the best coating

approach will be concluded for each specific application.



Foreseen internal meetings

Purpose Place Participants Date

Detailed breakdown of roles, tasks and deadlines

of Task 5.1

To be defined KLO, MAR, CDB,

DGA, ICONE, INDA,

CTEC and NSC.

At least 4 months before

(M9)


of Task 5.2

To be defined AITEX, UPC, BIU,

CENTI At least 4

months before (M9)

Detailed breakdown of roles, tasks and deadlines of Task 5.3 (5.3.1, 5.3.2,

5.3.3)

To be defined AITEX, UPC, BIU, At least 4 months before

(M9)


of Task 5.4

To be defined CDB, MAR, KLO,

FN

At least 4 months before

(M20)



Foreseen internal deliverables

Purpose From To What Date


wp5 - protectprotect-h2020.eu/wp-content/uploads/2017/05/ko_wp5...gantt wp5 wp/t no. wps/tasks name...

Documents